Phosphorus, New York, has formed a partnership with BioIQ, Atlanta, to make Phosphorus’ at-home saliva test for covid-19 accessible to people across the United States. The Phosphorus covid-19 saliva test has been granted FDA emergency use authorization. Using a saliva-based collection method at home is simpler and less intrusive than the prevalent swab-based methods.
BioIQ developed a health technology platform to support digital symptom and exposure assessment, contact tracing, and follow-up care navigation that will help connect employees as well as healthcare plan members to this testing. Phosphorus is also making its tests available to healthcare partners as well as to the general public, who can order the test online.
“Phosphorus is excited about this partnership with BioIQ. We understand that testing is essential when it comes to re-opening the economy, and this alliance will ensure that people from coast to coast have access to safe, efficient and effective covid testing,” says Alexander Bisignano, co-founder and chief executive officer of Phosphorus. “We’re committed to back-to-work and other similar initiatives and motivated to work with similar programs across the country.”
“Additional RT-PCR covid-19 testing capacity and convenience through home sample collection is a critical need for employers, health plans, and government agencies,” says Justin Bellante, BioIQ chief executive officer. “The partnership with Phosphorus adds the sophistication and validation of a leading genomics laboratory to our network and the expanded use of home sample collection and testing for covidD-19.”